<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02675088</url>
  </required_header>
  <id_info>
    <org_study_id>CH-L-045/1</org_study_id>
    <nct_id>NCT02675088</nct_id>
  </id_info>
  <brief_title>Comparable Study of Different Thoracic Radiotherapy Regimens for Extensive Stage Small Cell Lung Cancer</brief_title>
  <official_title>Randomized Phase III Study Comparing Different Thoracic Radiotherapy Regimens in Patients With Extensive Stage Small Cell Lung Cancer Who Respond to Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>West China Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhejiang Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tianjin Medical University Cancer Institute and Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chinese Academy of Medical Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Most patients with extensive stage small-cell lung cancer (ES-SCLC) who undergo chemotherapy,
      and prophylactic cranial irradiation, have persistent intrathoracic disease. A Dutch study
      recently proved that thoracic radiotherapy(TRT), using 30 Gy in 10 fractions of 3 Gy, could
      improve 2-year overall survival(OS) of this patient group compared with non-TRT group. But
      intrathoracic progression was still high, either with or without progression elsewhere,
      occurring in 43.7% in the TRT group. The ideal TRT regimen for ES-SCLC is undefined. Maybe
      higher dose can provide better local control(LC) and overall survival. In this study, the
      investigators propose to give an increased dose of TRT to determine whether higher dose will
      improve 2-year OS, LC and progression-free survival.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, prospective, randomised phase III study. For patients with ES-SCLC who
      respond to chemotherapy after four to six cycles of standard chemotherapy (platinum
      etoposide), 45Gy/15F of thoracic radiotherapy will be used in experimental arm, while
      30Gy/10F of thoracic radiotherapy will be used in the control arm. Both survival and toxicity
      of the two arms will be observed and compared.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall survival</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>progression-free survival</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of tumor recurrence in local or regional area</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of radiotherapy and chemotherapy induced toxicities assessed by CTCAE v 4.0</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">186</enrollment>
  <condition>Carcinoma, Small Cell</condition>
  <condition>Lung Neoplasms</condition>
  <arm_group>
    <arm_group_label>high-dose TRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>high-dose thoracic radiotherapy X-ray RT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>standard-dose TRT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>standard-dose thoracic radiotherapy XRT</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>high-dose TRT</intervention_name>
    <description>every day, Monday-Friday, for a total of 3 weeks, 45 Gy/ 3 Gy/ 15 f</description>
    <arm_group_label>high-dose TRT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>standard-dose TRT</intervention_name>
    <description>every day, Monday-Friday, for a total of 2 weeks, 30 Gy/ 3 Gy/ 10 f</description>
    <arm_group_label>standard-dose TRT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 - 70 years old, ECOG 0-2.

          -  Patients with histologically or cytologically proved small cell lung cancer.

          -  Extensive stage small-cell lung cancer (ES-SCLC), was characterized by tumors beyond
             the hemithorax, hilar, mediastinal, and supraclavicular nodes. According to 2007 AJCC
             cancer staging 7th edition, stage I-IIIB with lung metastases and stage IV should be
             defined as LD.

          -  Has 1-4 extracranial metastatic lesions.

          -  No brain or central nervous system (CNS) metastases.

          -  No prior history of anti-tumor treatment.

          -  Response after 4 to 6 cycles of EP-based chemotherapy within the past 4 weeks.

          -  No severe internal diseases and no organ dysfunction.

          -  Written informed consent provided.

        Exclusion Criteria:

          -  Malignant tumors of other sites. Non melanoma skin cancer and Cervical carcinoma in
             situ were not included if curable.

          -  Active heart disease or acute myocardial infarction happen in six months.

          -  Psychiatric history.

          -  Pregnant woman or woman need to breast feed or woman with positive chorionic
             gonadotrophin (HCG).

          -  Uncontrolled diabetes or hypertension.

          -  Interstitial pneumonia or Active pulmonary fibrosis.

          -  Acute bacterial or fungal infection.

          -  Oral or intravenous use of steroids.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>LuHua Wang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Hospital of CAMS</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>LuHua Wang, MD</last_name>
    <phone>+861087788799</phone>
    <email>wlhwq@yahoo.com</email>
  </overall_contact>
  <results_reference>
    <citation>Slotman BJ, van Tinteren H, Praag JO, Knegjens JL, El Sharouni SY, Hatton M, Keijser A, Faivre-Finn C, Senan S. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Lancet. 2015 Jan 3;385(9962):36-42. doi: 10.1016/S0140-6736(14)61085-0. Epub 2014 Sep 14. Erratum in: Lancet. 2015 Jan 3;385(9962):28.</citation>
    <PMID>25230595</PMID>
  </results_reference>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 3, 2016</study_first_submitted>
  <study_first_submitted_qc>February 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 5, 2016</study_first_posted>
  <last_update_submitted>February 5, 2016</last_update_submitted>
  <last_update_submitted_qc>February 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Luhua Wang</investigator_full_name>
    <investigator_title>Vice President of Cancer hospital of CAMS</investigator_title>
  </responsible_party>
  <keyword>Extensive Stage Small Cell Lung Cancer</keyword>
  <keyword>thoracic radiotherapy</keyword>
  <keyword>radiotherapy regimen</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Small Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

